Therefore, prospective randomised trials are required to determine the impact of 177Lu-PSMA on survival, toxicities, dosimetry, and to rigorously assess the clinical benefits compared to other treatments for prostate cancer, including chemotherapy, EBRT, and androgen blockade. This evidence concerns the gene FOLH1 and prostate cancer.